Translating immune cell cross-talk into a treatment opportunity for visceral leishmaniasis

Abstract

Results from both murine and human studies suggest the emergence of immunotherapy, involving different agonists and antagonists to the cytokines and cells involved in the course of disease progression, as a promising treatment option against visceral leishmaniasi